Thermo Fisher Scientific (TMO) 10-Q 2 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 29, 2018shares
Document and Entity Information [Abstract]
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Central Index Key	97,745
Document Type	10-Q
Document Period End Date	Sep. 29, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	402,576,382
Entity Stock Trading Symbol	TMO

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 1,098	$ 1,335
Accounts receivable, less allowances of $116 and $109	3,852	3,879
Inventories	2,982	2,971
Refundable income taxes	405	432
Other current assets	1,229	804
Total current assets	9,566	9,421
Property, Plant and Equipment, Net	3,978	4,047
Acquisition-related Intangible Assets, Net	15,219	16,684
Other Assets	1,173	1,227
Goodwill	25,142	25,290
Total Assets	55,078	56,669
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	1,014	2,135
Accounts payable	1,344	1,428
Accrued payroll and employee benefits	817	918
Contract liabilities	797	0
Deferred revenue	0	719
Other accrued expenses	1,224	1,848
Total current liabilities	5,196	7,048
Deferred Income Taxes	2,550	2,766
Other Long-term Liabilities	2,682	2,569
Long-term Obligations	17,760	18,873
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 431,007,744 and 428,327,873 shares issued	431	428
Capital in excess of par value	14,526	14,177
Retained earnings	17,866	15,914
Treasury stock at cost, 28,431,362 and 27,013,311 shares	3,414	3,103
Accumulated other comprehensive items	(2,519)	(2,003)
Total shareholders' equity	26,890	25,413
Total Liabilities and Shareholders' Equity	$ 55,078	$ 56,669

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 116	$ 109
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	431,007,744	428,327,873
Treasury Stock at Cost (in shares)	28,431,362	27,013,311

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Revenues
Revenues	$ 5,920	$ 5,116	$ 17,851	$ 14,871
Costs and Operating Expenses:
Selling, general and administrative expenses	1,490	1,400	4,547	4,025
Research and development expenses	240	217	716	654
Restructuring and other (income) costs, net	(27)	49	35	95
Total costs and operating expenses	5,008	4,482	15,216	12,868
Operating Income	912	634	2,635	2,003
Other Expense, Net	(102)	(154)	(385)	(394)
Income from Continuing Operations Before Income Taxes	810	480	2,250	1,609
(Provision for) Benefit from Income Taxes	(101)	54	(210)	89
Income from Continuing Operations	709	534	2,040	1,698
Loss from Discontinued Operations (net of income tax benefit of $0, $0, $0 and $0)	0	0	0	(1)
Net Income	$ 709	$ 534	$ 2,040	$ 1,697
Earnings per Share from Continuing Operations
Basic (in dollars per share)	$ 1.76	$ 1.35	$ 5.07	$ 4.33
Diluted (in dollars per share)	1.75	1.34	5.03	4.29
Earnings per Share
Basic (in dollars per share)	1.76	1.35	5.07	4.32
Diluted (in dollars per share)	$ 1.75	$ 1.34	$ 5.03	$ 4.29
Weighted Average Shares
Basic (in shares)	402	396	402	392
Diluted (in shares)	406	400	406	396
Product [Member]
Revenues
Revenues	$ 4,571	$ 4,232	$ 13,807	$ 12,632
Costs and Operating Expenses:
Cost of revenues	2,357	2,174	7,072	6,547
Service [Member]
Revenues
Revenues	1,349	884	4,044	2,239
Costs and Operating Expenses:
Cost of revenues	$ 948	$ 642	$ 2,846	$ 1,547

Consolidated Statement of Inc_2

Consolidated Statement of Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Income Statement [Abstract]
Provision for (Benefit from) Income Taxes on Income (Loss) from Discontinued Operations	$ 0	$ 0	$ 0	$ 0

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Comprehensive Income
Net Income	$ 709	$ 534	$ 2,040	$ 1,697
Other Comprehensive Items:
Currency translation adjustment (net of tax provision of $13, $0, $60 and $0)	(32)	73	(447)	452
Unrealized gains and losses on available-for-sale investments:
Unrealized holding gains arising during the period (net of tax provision of $0, ($1), $0 and $0)	0	(2)	0	0
Reclassification adjustment for (gains) losses included in net income (net of tax (provision) benefit of $0, $0, $0 and ($1))	0	0	0	(1)
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $1, $3 and $3)	2	2	6	6
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $0, ($2), $1 and ($5))	0	(2)	3	(11)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $0, $1, $3 and $3)	2	2	10	7
Total other comprehensive items	(28)	73	(428)	453
Comprehensive Income	$ 681	$ 607	$ 1,612	$ 2,150

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 13	$ 0	$ 60	$ 0
Tax provision (benefit) on unrealized holding gains and losses on available-for-sale investments arising during the period	0	(1)	0	0
Tax provision (benefit) on reclassification adjustment for gains on available-for-sale investments recognized in net income	0	0	0	1
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	(1)	(1)	(3)	(3)
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	0	(2)	1	(5)
Tax provision (benefit) on amortization of net loss and prior service benefit included in net periodic pension cost	$ 0	$ (1)	$ (3)	$ (3)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017
Operating Activities
Net Income	$ 2,040	$ 1,697
Loss from discontinued operations	0	1
Income from continuing operations	2,040	1,698
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,709	1,459
Change in deferred income taxes	(317)	(484)
Non-cash stock-based compensation	137	116
Non-cash charges for sale of inventories revalued at the date of acquisition	10	47
Other non-cash expenses, net	67	67
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
Accounts receivable	(64)	(161)
Inventories	(333)	(208)
Other assets	(137)	(233)
Accounts payable	(45)	0
Other liabilities	(247)	24
Contributions to retirement plans	(78)	(184)
Net cash provided by continuing operations	2,742	2,141
Net cash used in discontinued operations	0	(2)
Net cash provided by operating activities	2,742	2,139
Investing Activities
Acquisitions, net of cash acquired	(59)	(7,160)
Purchase of property, plant and equipment	(474)	(293)
Proceeds from sale of property, plant and equipment	6	4
Other investing activities, net	(5)	3
Net cash used in investing activities	(532)	(7,446)
Financing Activities
Net proceeds from issuance of debt	690	6,459
Repayment of debt	(2,048)	(2,552)
Proceeds from issuance of commercial paper	3,378	6,030
Repayments of commercial paper	(3,842)	(5,809)
Purchases of company common stock	(250)	(750)
Dividends paid	(198)	(177)
Net proceeds from issuance of company common stock	0	1,690
Net proceeds from issuance of company common stock under employee stock plans	97	108
Other financing activities	(51)	(1)
Net cash (used in) provided by financing activities	(2,224)	4,998
Exchange Rate Effect on Cash	(236)	256
Decrease in Cash, Cash Equivalents and Restricted Cash	(250)	(53)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	1,361	811
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 1,111	$ 758

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2016		415			22
Balance at Dec. 31, 2016	$ 21,540	$ 415	$ 12,140	$ 13,927	$ (2,306)	$ (2,636)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		3			0
Issuance of shares under employees' and directors' stock plans	131	$ 3	173		$ (45)
Issuance of shares (in shares)		10
Issuance of shares	1,690	$ 10	1,680
Stock-based compensation	116		116
Purchases of company common stock (in shares)					5
Purchases of company common stock	(750)				$ (750)
Dividends declared	(178)			(178)
Net Income	1,697			1,697
Other comprehensive items	453					453
Other	3		3
Balance (in shares) at Sep. 30, 2017		428			27
Balance at Sep. 30, 2017	24,702	$ 428	14,112	15,446	$ (3,101)	(2,183)
Balance (in shares) at Jul. 01, 2017		417			27
Balance at Jul. 01, 2017	22,391	$ 417	12,328	14,972	$ (3,070)	(2,256)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1
Issuance of shares under employees' and directors' stock plans	23	$ 1	53		$ (31)
Issuance of shares (in shares)		10
Issuance of shares	1,690	$ 10	1,680
Stock-based compensation	45		45
Dividends declared	(60)			(60)
Net Income	534			534
Other comprehensive items	73					73
Other	6		6
Balance (in shares) at Sep. 30, 2017		428			27
Balance at Sep. 30, 2017	24,702	$ 428	14,112	15,446	$ (3,101)	(2,183)
Balance (in shares) at Dec. 31, 2017		428			27
Balance at Dec. 31, 2017	25,413	$ 428	14,177	15,914	$ (3,103)	(2,003)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting changes	30			118		(88)
Issuance of shares under employees' and directors' stock plans (in shares)		3			0
Issuance of shares under employees' and directors' stock plans	127	$ 3	185		$ (61)
Stock-based compensation	137		137
Purchases of company common stock (in shares)					1
Purchases of company common stock	(250)				$ (250)
Dividends declared	(206)			(206)
Net Income	2,040			2,040
Other comprehensive items	(428)					(428)
Other	27		27
Balance (in shares) at Sep. 29, 2018		431			28
Balance at Sep. 29, 2018	26,890	$ 431	14,526	17,866	$ (3,414)	(2,519)
Balance (in shares) at Jun. 30, 2018		430			27
Balance at Jun. 30, 2018	26,445	$ 430	14,408	17,226	$ (3,128)	(2,491)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1			0
Issuance of shares under employees' and directors' stock plans	37	$ 1	72		$ (36)
Stock-based compensation	46		46
Purchases of company common stock (in shares)					1
Purchases of company common stock	(250)				$ (250)
Dividends declared	(69)			(69)
Net Income	709			709
Other comprehensive items	(28)					(28)
Balance (in shares) at Sep. 29, 2018		431			28
Balance at Sep. 29, 2018	$ 26,890	$ 431	$ 14,526	$ 17,866	$ (3,414)	$ (2,519)

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.17	$ 0.15	$ 0.51	$ 0.45

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 29, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1 . Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at September 29, 2018 , the results of operations for the three- and nine-month periods ended September 29, 2018 and September 30, 2017 , and the cash flows for the nine-month periods ended September 29, 2018 and September 30, 2017 . Interim results are not necessarily indicative of results for a full year. The consolidated balance sheet presented as of December 31, 2017 , has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2017 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Note 1 to the consolidated financial statements for 2017 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. Except for the accounting for revenue arising from contracts with customers, as noted below, there have been no material changes in the company’s significant accounting policies during the nine months ended September 29, 2018 . Revenue Recognition The company recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (clinical trial logistics, pharmaceutical development and manufacturing services, asset management, diagnostic testing, training, service contracts, and field services including related time and materials) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated as inputs to measure progress. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. Payments from customers for most instruments, consumables and services are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g. extended service contracts), upon completion of the service (e.g. pharmaceutical development and manufacturing) or a mix of both. See Note 3 for revenue disaggregated by type and by geographic region as well as further information about remaining performance obligations. Contract-related Balances Contract assets include revenues recognized in advance of billings and are recorded net of estimated losses resulting from the inability to invoice customers. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Current contract assets and noncurrent contract assets are included within other current assets and other assets, respectively, in the accompanying balance sheet. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: September 29, January 1, (In millions) 2018 2018 Current Contract Assets, Net $ 462 $ 396 Current Contract Liabilities 797 805 Noncurrent Contract Liabilities 349 302 Noncurrent contract assets were immaterial in 2018 . In the first nine months of 2018 , the company recognized revenue of $591 million that was included in the contract liabilities balance at January 1, 2018 . Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Nine Months Ended September 29, September 30, (In millions) 2018 2017 Beginning Balance $ 87 $ 78 Provision charged to income 89 76 Usage (80 ) (75 ) Acquisitions — 1 Adjustments to previously provided warranties, net (3 ) (2 ) Currency translation (2 ) 3 Ending Balance $ 91 $ 81 Inventories The components of inventories are as follows: September 29, December 31, (In millions) 2018 2017 Raw Materials $ 807 $ 708 Work in Process 433 505 Finished Goods 1,742 1,758 Inventories $ 2,982 $ 2,971 Property, Plant and Equipment Property, plant and equipment consists of the following: September 29, December 31, (In millions) 2018 2017 Land $ 392 $ 401 Buildings and Improvements 1,677 1,662 Machinery, Equipment and Leasehold Improvements 4,536 4,276 Property, Plant and Equipment, at Cost 6,605 6,339 Less: Accumulated Depreciation and Amortization 2,627 2,292 Property, Plant and Equipment, Net $ 3,978 $ 4,047 Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at September 29, 2018 Balance at December 31, 2017 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite Lived: Customer relationships $ 17,092 $ (6,592 ) $ 10,500 $ 17,356 $ (5,902 ) $ 11,454 Product technology 6,003 (3,143 ) 2,860 6,046 (2,811 ) 3,235 Tradenames 1,512 (920 ) 592 1,538 (817 ) 721 Other 33 (33 ) — 34 (34 ) — 24,640 (10,688 ) 13,952 24,974 (9,564 ) 15,410 Indefinite Lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 In-process research and development 32 N/A 32 39 N/A 39 1,267 N/A 1,267 1,274 N/A 1,274 Acquisition-related Intangible Assets $ 25,907 $ (10,688 ) $ 15,219 $ 26,248 $ (9,564 ) $ 16,684 Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2 ) and the ultimate loss from abandoning leases at facilities being exited (Note 13 ). Actual results could differ from those estimates. Recent Accounting Pronouncements In August 2018, the FASB issued new guidance to align the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Under the new guidance, certain implementation costs that previously were required to be expensed will be capitalized and amortized over the term of the hosting arrangement. The company plans to adopt the guidance in the fourth quarter of 2018 prospectively to all implementation costs incurred after the date of adoption. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company expects to adopt the guidance when it is effective in 2020 using a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company expects to adopt the guidance when it is effective in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In August 2018, the SEC adopted amendments to certain disclosure requirements effective November 5, 2018, including those relating to an interim presentation of the statement of shareholders’ equity. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In February 2018, the FASB issued new guidance to allow reclassifications from accumulated other comprehensive items (AOCI) to retained earnings for certain tax effects on items within AOCI resulting from the Tax Cuts and Jobs Act of 2017 (the Tax Act). The company adopted this guidance in January 2018 and recorded the reclassifications in the period of adoption. The balance sheet impact of adopting this guidance is included in the table below. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, the company reclassifies the tax effects to the consolidated statement of income on an item-by-item basis when the pre-tax item in AOCI is reclassified to income. In December 2017, the SEC staff issued guidance to address the application of accounting guidance in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act enacted on December 22, 2017. The company reported provisional amounts in its 2017 financial statements for certain income tax effects of the Tax Act for which a reasonable estimate could be determined but for which the accounting impact may change. For example, these estimates may be impacted by the need for further analysis and future clarification and guidance regarding available tax accounting methods and elections, earnings and profits computations and state tax conformity to federal changes. Adjustments to provisional amounts identified during the measurement period, which may be up to December 22, 2018, will be included as adjustments to Provision for Income Taxes in the period the amounts are determined (Note 6 ). In August 2017, the FASB issued new guidance to simplify the application of hedge accounting guidance. Among other things, the new guidance will permit more hedging strategies to qualify for hedge accounting, allow for additional time to perform an initial assessment of a hedge’s effectiveness, and permit a qualitative effectiveness test for certain hedges after initial qualification. The company adopted this guidance in January 2018. The balance sheet impact of adopting this guidance is included in the table below. In March 2017, the FASB issued new guidance intended to improve the presentation of net periodic pension cost and net periodic postretirement benefit cost. The new guidance requires the service cost component of net periodic cost be reported in the same line item(s) as other employee compensation costs and all other components of the net periodic cost be reported in the income statement below operating income. The company adopted this guidance on January 1, 2018 and applied the changes to the statement of income retrospectively. As a result of adoption of this guidance, the accompanying 2017 statement of income reflects the following changes from previously reported amounts: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2017 2017 Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses) $ 2 $ 7 Decrease in Operating Income 2 7 Increase in Other Income (Expense) 2 7 In January 2017, the FASB issued new guidance clarifying the definition of a business and providing criteria to determine when an integrated set of assets and activities is not defined as a business. The new guidance requires such integrated sets to be defined as an asset (and not a business) if substantially all of the fair value of the gross assets acquired or disposed is concentrated in a single identifiable asset or a group of similar identifiable assets. The adoption of this guidance as of January 1, 2018 did not have a material impact on the company’s consolidated financial statements. In October 2016, the FASB issued new guidance eliminating the deferral of the tax effects of intra-entity asset transfers. The impact of this guidance in future periods will be dependent on the extent of future asset transfers which usually occur in connection with planning around acquisitions and other business structuring activities. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below. In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The guidance is effective for the company in 2020 using a modified retrospective method and early adoption is permitted. The company is currently evaluating the timing of adoption. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 and 2018, the FASB issued additional guidance and clarification. The company plans to adopt the guidance on January 1, 2019, using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods will not be restated. The company is currently evaluating the impact of this guidance by considering which practical expedients to elect, deploying a software tool to assist in the accounting calculations, surveying functional groups that oversee vendor relationships, and developing processes and controls to manage the changes in the lease guidance and gather information for the required disclosures. The company expects that assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities; however, the adoption of this guidance is not expected to have a material impact on the company’s results of operations or cash flows. The company’s future commitments under lease obligations are summarized in Note 10 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K, filed with the SEC. In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below. In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most previous revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During 2016 and 2017, the FASB issued additional guidance and clarification, including the elimination of certain SEC Staff Guidance. The guidance is effective for the company in 2018. The company elected to adopt this guidance through application of the modified retrospective method by applying it to contracts that were not completed as of December 31, 2017 (in addition to new contracts in 2018). Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows: (In millions) December 31, Impact of Adopting New Revenue Guidance Impact of Adopting New Equity Investment Guidance Impact of Adopting New Intra-entity Tax Guidance Impact of Adopting New Hedge Accounting Guidance Impact of Adopting New Tax Effects on Items in AOCI Guidance January 1, 2018 Accounts Receivable, Less Allowances $ 3,879 $ (8 ) $ — $ — $ — $ — $ 3,871 Inventories 2,971 (252 ) — — — — 2,719 Other Current Assets 804 296 — — — — 1,100 Other Assets 1,227 — — (77 ) — — 1,150 Contract Liabilities — 805 — — — — 805 Deferred Revenue 719 (719 ) — — — — — Other Accrued Expenses 1,848 (153 ) — — — — 1,695 Deferred Income Taxes 2,766 — — (57 ) — 2 2,711 Other Long-term Liabilities 2,569 54 — — — — 2,623 Long-term Obligations 18,873 — — — (3 ) — 18,870 Retained Earnings 15,914 49 (1 ) (20 ) 3 87 16,032 Accumulated Other Comprehensive Items (2,003 ) — 1 — — (89 ) (2,091 ) Had the company continued to use the revenue recognition guidance in effect prior to 2018, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the three and nine months ended September 29, 2018 , from am ounts reported therein. However, inventories would have b een $329 million higher and other current assets would have been $339 million lower as of September 29, 2018 , primarily as a result of differences in the accounting for pharmaceutical development and manufacturing services under the new revenue guidance. Under the prior guidance, costs of these services were recorded in inventory while under the new guidance, costs are expensed as the manufacturing service is performed and the company's rights to consideration are recorded as contract assets and included in other current assets.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 29, 2018
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2 . Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. 2018 In 2018, the company acquired, within the Life Sciences Solutions segment, IntegenX Inc., a North America-based provider of a rapid DNA platform for use in forensics and law enforcement applications, for an aggregate purchase price of $65 million . On October 25, 2018, the company acquired, within the Life Sciences Solutions segment, Becton Dickinson and Company's Advanced Bioprocessing business for $477 million in cash, subject to post-closing adjustment. This North America-based business adds complementary cell culture products that expand the segment's bioproduction offerings to help customers increase yield during production of biologic drugs. Revenues of the Advanced Bioprocessing business were $100 million in 2017. The company expects to determine the preliminary purchase price allocation prior to the end of the fourth quarter of 2018. The company has entered into an agreement to acquire Gatan, Inc., a wholly owned subsidiary of Roper Technologies, Inc., for approximately $925 million in cash. Gatan is a leading manufacturer of instrumentation and software used to enhance and extend the operation and performance of electron microscopes. The transaction, which is expected to be completed by the end of 2018, is subject to customary closing conditions, including regulatory approvals. Unaudited Pro Forma Information The following unaudited pro forma information provides the effect of the company's acquisition of Patheon as if the acquisition had occurred on January 1, 2016: Three Months Ended Nine Months Ended September 30, September 30, (In millions except per share amounts) 2017 2017 Revenues $ 5,393 $ 16,076 Net Income $ 522 $ 1,671 The historical consolidated financial information of the company and Patheon has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the acquisition and related financing arrangements, are expected to have a continuing impact on the company, and are factually supportable. To reflect the acquisition of Patheon as if it had occurred on January 1, 2016, the unaudited pro forma results include adjustments to reflect, among other things, the incremental intangible asset amortization to be incurred based on the values of each identifiable intangible asset and the interest expense from debt financing obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been realized had the acquisition of Patheon and related financing occurred on January 1, 2016, nor are they meant to be indicative of any anticipated combined results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized subsequent to the transaction. Pro forma net income for the nine months ended September 30, 2017, excludes certain items associated with the Patheon acquisition that were included in the determination of net income for that period. These items have been included in the determination of pro forma net income for the nine months ended October 1, 2016 and are as follows: $42 million of direct transaction costs, $33 million of accounting policy conformity adjustments, $18 million of initial restructuring costs, $18 million reduction of revenues for revaluing the deferred revenue obligations to fair value, and $15 million of expense related to the fair value adjustment to acquisition-date inventories. The company’s results would not have been materially different from its pro forma results had the company’s other 2018 or 2017 acquisitions occurred at the beginning of 2017 or 2016, respectively.

Revenue

Revenue	9 Months Ended
	Sep. 29, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3 . Revenue Disaggregated Revenue Revenue by type is as follows: Three Months Ended Nine Months Ended September 29, September 29, (In millions) 2018 2018 Revenues Consumables 3,056 $ 9,345 Instruments 1,515 4,462 Services 1,349 4,044 Consolidated revenues $ 5,920 $ 17,851 Revenue by geographic region is as follows: Three Months Ended Nine Months Ended September 29, September 29, (In millions) 2018 2018 Revenues North America $ 3,030 $ 8,975 Europe 1,454 4,521 Asia-Pacific 1,251 3,809 Other regions 185 546 Consolidated revenues $ 5,920 $ 17,851 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See note 4 for revenue by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of September 29, 2018 was $5.12 billion . The company will recognize revenue for these performance obligations as they are satisfied, approximately 90% of which is expected to occur within the next twelve months .

Business Segment and Geographic

Business Segment and Geographical Information	9 Months Ended
	Sep. 29, 2018
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4 . Business Segment and Geographical Information The company’s financial performance is reported in four segments. A description of each segment follows. Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services: provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial and healthcare settings. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical trials logistics and commercial drug manufacturing. The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. Business Segment Information Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Revenues Life Sciences Solutions $ 1,504 $ 1,382 $ 4,572 $ 4,150 Analytical Instruments 1,333 1,189 3,901 3,407 Specialty Diagnostics 894 844 2,773 2,572 Laboratory Products and Services 2,470 1,933 7,433 5,424 Eliminations (281 ) (232 ) (828 ) (682 ) Consolidated revenues 5,920 5,116 17,851 14,871 Segment Income (a) Life Sciences Solutions 495 452 1,534 1,333 Analytical Instruments 294 257 831 681 Specialty Diagnostics 223 218 719 685 Laboratory Products and Services 299 243 916 704 Subtotal reportable segments (a) 1,311 1,170 4,000 3,403 Cost of revenues credits (charges), net 1 (45 ) (7 ) (77 ) Selling, general and administrative credits (charges), net 4 (37 ) (7 ) (75 ) Restructuring and other income (costs), net 27 (49 ) (35 ) (95 ) Amortization of acquisition-related intangible assets (431 ) (405 ) (1,316 ) (1,153 ) Consolidated operating income 912 634 2,635 2,003 Other expense, net (b) (102 ) (154 ) (385 ) (394 ) Income from continuing operations before income taxes $ 810 $ 480 $ 2,250 $ 1,609 Depreciation Life Sciences Solutions $ 29 $ 32 $ 89 $ 97 Analytical Instruments 18 17 53 51 Specialty Diagnostics 19 19 56 54 Laboratory Products and Services 66 44 195 104 Consolidated depreciation $ 132 $ 112 $ 393 $ 306 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments. Geographical Information Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Revenues (c) United States $ 2,918 $ 2,454 $ 8,588 $ 7,315 China 629 523 1,818 1,476 Other 2,373 2,139 7,445 6,080 Consolidated revenues $ 5,920 $ 5,116 $ 17,851 $ 14,871 (c) Revenues are attributed to countries based on customer location.

Other Expense, Net

Other Expense, Net	9 Months Ended
	Sep. 29, 2018
Other Income and Expenses [Abstract]
Other Expense, Net [Text Block]	Note 5 . Other Expense, Net The components of other expense, net, in the accompanying statement of income are as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Interest Income $ 41 $ 25 $ 92 $ 61 Interest Expense (162 ) (157 ) (495 ) (426 ) Other Items, Net 19 (22 ) 18 (29 ) Other Expense, Net $ (102 ) $ (154 ) $ (385 ) $ (394 ) Other Items, Net In all periods, other items, net includes currency transaction gains and losses on monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 29, 2018
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 6 . Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine Months Ended September 29, September 30, (In millions) 2018 2017 Statutory Federal Income Tax Rate 21 % 35 % Provision for Income Taxes at Statutory Rate $ 473 $ 563 Increases (Decreases) Resulting From: Foreign rate differential (177 ) (287 ) Foreign exchange loss on inter-company debt refinancing — (237 ) Income tax credits (183 ) (101 ) Global intangible low-taxed income 124 — Foreign-derived intangible income (34 ) — Withholding taxes — 49 Singapore tax holiday (29 ) (17 ) Impact of change in tax laws and apportionment on deferred taxes 14 (60 ) Transition tax and other initial impacts of U.S. tax reform 117 — (Reversal of) provision for tax reserves, net (49 ) 13 Excess tax benefits from stock options and restricted stock units (59 ) (51 ) Valuation allowance — 50 Other, net 13 (11 ) Provision for (benefit from) income taxes $ 210 $ (89 ) The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. In the first quarter of 2018, the company recorded a net tax provision of $21 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017, consisting of an incremental provision of $70 million offset in part by a $49 million reduction of related unrecognized tax benefits established in 2017. In the third quarter of 2018, the company recorded an incremental provision of $47 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017. These adjustments were required based on new U.S. Treasury guidance and further analysis of available tax accounting methods and elections, legislative updates, regulations, earnings and profits computations and taxpools. The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2026 . In 2018 and 2017 , the impact of this tax holiday decreased the annual effective tax rates by 1.3 percentage points and 1.1 percentage point, respectively, and increased diluted earnings per share by approximately $0.07 and $0.04 , respectively. Unrecognized Tax Benefits As of September 29, 2018 , the company had $1.37 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2018 Balance at beginning of year $ 1,409 Reductions due to acquisitions (9 ) Additions for tax positions of current year 5 Additions for tax positions of prior years 88 Reductions for tax positions of prior years (69 ) Settlements (52 ) Balance at end of period $ 1,372

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 29, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 7 . Earnings per Share Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions except per share amounts) 2018 2017 2018 2017 Income from Continuing Operations $ 709 $ 534 $ 2,040 $ 1,698 Loss from Discontinued Operations — — — (1 ) Net Income $ 709 $ 534 $ 2,040 $ 1,697 Basic Weighted Average Shares 402 396 402 392 Plus Effect of: Stock options and restricted units 4 4 4 4 Diluted Weighted Average Shares 406 400 406 396 Basic Earnings per Share: Continuing operations $ 1.76 $ 1.35 $ 5.07 $ 4.33 Discontinued operations — — — — Basic Earnings per Share $ 1.76 $ 1.35 $ 5.07 $ 4.32 Diluted Earnings per Share: Continuing operations $ 1.75 $ 1.34 $ 5.03 $ 4.29 Discontinued operations — — — — Diluted Earnings per Share $ 1.75 $ 1.34 $ 5.03 $ 4.29 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 2 2 2 2

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	9 Months Ended
	Sep. 29, 2018
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 8 . Debt and Other Financing Arrangements Effective Interest Rate at September 29, September 29, December 31, (Dollars in millions) 2018 2018 2017 Commercial Paper — % $ 429 $ 960 Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated) — 721 2.15% 3-Year Senior Notes, Due 12/14/2018 — 450 2.40% 5-Year Senior Notes, Due 2/1/2019 — 900 Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) 0.10 % 581 600 6.00% 10-Year Senior Notes, Due 3/1/2020 2.98 % 750 750 4.70% 10-Year Senior Notes, Due 5/1/2020 4.23 % 300 300 Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) 0.16 % 696 — 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) 1.62 % 493 510 5.00% 10-Year Senior Notes, Due 1/15/2021 3.25 % 400 400 4.50% 10-Year Senior Notes, Due 3/1/2021 7.06 % 1,000 1,000 3.60% 10-Year Senior Notes, Due 8/15/2021 6.83 % 1,100 1,100 3.30% 7-Year Senior Notes, Due 2/15/2022 3.42 % 800 800 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 581 600 3.15% 10-Year Senior Notes, Due 1/15/2023 3.30 % 800 800 3.00% 7-Year Senior Notes, Due 4/15/2023 7.11 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,160 1,201 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 743 768 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 812 840 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 581 600 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 696 721 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 812 840 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 812 840 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 Other 22 24 Total Borrowings at Par Value 19,018 21,175 Fair Value Hedge Accounting Adjustments (143 ) (70 ) Unamortized Discount, Net (16 ) (2 ) Unamortized Debt Issuance Costs (85 ) (95 ) Total Borrowings at Carrying Value 18,774 21,008 Less: Short-term Obligations and Current Maturities 1,014 2,135 Long-term Obligations $ 17,760 $ 18,873 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging. See Note 11 for fair value information pertaining to the company’s long-term obligations. Credit Facilities The company has a revolving credit facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021 . The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in Euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 3.5 :1.0. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0 :1.0 as of the last day of any fiscal quarter. As of September 29, 2018 , no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $83 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of September 29, 2018 , outstanding borrowings under these programs were $429 million , with a weighted average remaining period to maturity of 8 days and are classified as short-term obligations in the accompanying balance sheet. Senior Notes Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company, issued the Floating Rate Senior Notes due 2020 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2020 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations. Interest Rate Swap Arrangements and related Cross-currency Interest Rate Swap Arrangements The company has entered into LIBOR-based interest rate swap arrangements with various banks on several of its outstanding senior notes. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 11 for additional information on the interest rate swap arrangements and related cross-currency interest rate swap arrangements. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at September 29, 2018 : Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate September 29, Receive Rate 4.50% Senior Notes due 2021 (a) 1,000 1-month LIBOR + 3.4420% 5.5458 % 4.50 % 3.60% Senior Notes due 2021 1,100 1-month LIBOR + 2.5150% 4.6734 % 3.60 % 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 3.9224 % 3.00 % (a) The payments on $1.2 billion notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of September 29, 2018 from a weighted average of 4.73% to a weighted average of 1.97% . In 2018, the company entered into $1.2 billion notional value of cross-currency interest rate swaps, which effectively convert a portion of the semi-annual payments related to the variable rate, U.S. dollar denominated, LIBOR-based interest rate swaps to payments on variable rate, euro denominated, EURIBOR-based cross-currency interest rate swaps.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 29, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 9 . Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At September 29, 2018 , the company’s total environmental liability was approximately $50 million . While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2017 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Intellectual Property Matters On May 26, 2010, Promega Corp. & Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften EV filed a complaint against Life Technologies in the United States District Court for the Western District of Wisconsin. The plaintiffs allege patent infringement by sales and uses of Applied Biosystems’ short tandem repeat DNA identification products outside the scope of a 2006 license agreement. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. Although a jury initially found willful infringement and assessed damages at $52 million the District Court subsequently overturned the verdict on the grounds that the plaintiff had failed to prove infringement. The District Court entered judgment in favor of Life Technologies; and plaintiffs and Life Technologies filed cross-appeals with the United States Court of Appeals for the Federal Circuit. The $52 million award was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. On December 15, 2014, the Court of Appeals issued a decision invalidating four of the plaintiffs’ patents, but finding infringement by Life Technologies of the remaining fifth patent. The Court of Appeals also ordered a new trial on damages in the District Court. Life Technologies' petition to the U.S. Supreme Court seeking review of the Court of Appeals’ judgment was granted on June 27, 2016, and the case was stayed in the District Court pending the outcome of the Supreme Court’s review. On February 22, 2017, the Supreme Court issued a decision reversing the Court of Appeals’ judgment and remanding the case to the Court of Appeals for further proceedings in view of the Supreme Court’s legal interpretation of the patent law statute in question. On November 13, 2017, the Court of Appeals issued a decision holding that Promega is not entitled to recover any damages and affirming the District Court’s grant of judgment in favor of Life Technologies and denial of Promega’s motion for a new trial. The Court of Appeals denied Promega’s petition for rehearing on February 14, 2018, and Promega filed a petition with the U.S. Supreme Court on June 14, 2018, seeking review of the Court of Appeals' decision. On October 1, 2018, the U.S. Supreme Court denied Promega's petition. As a result, the company reversed the $52 million accrual in the third quarter of 2018, and recorded the gain in restructuring and other costs (income), net, in the accompanying statement of income. On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product "supply centers" installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On August 24, 2017, Unisone filed an appeal from a decision by the Patent Trial and Appeal Board that found the challenged patent claims invalid.

Comprehensive Income and Shareh

Comprehensive Income and Shareholders Equity	9 Months Ended
	Sep. 29, 2018
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 10 . Comprehensive Income and Shareholders' Equity Comprehensive Income (Loss) Comprehensive income (loss) combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet. Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Unrealized Pension and Total Balance at December 31, 2017 $ (1,755 ) $ (1 ) $ (50 ) $ (197 ) $ (2,003 ) Cumulative effect of accounting changes (Note 1) (54 ) 1 (11 ) (24 ) (88 ) Other comprehensive income (loss) before reclassifications (447 ) — — 3 (444 ) Amounts reclassified from accumulated other comprehensive items — — 6 10 16 Net other comprehensive items (447 ) — 6 13 (428 ) Balance at September 29, 2018 $ (2,256 ) $ — $ (55 ) $ (208 ) $ (2,519 )

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	9 Months Ended
	Sep. 29, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 11 . Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2018 . The company’s financial assets and liabilities carried at fair value are primarily comprised of insurance contracts, investments in money market funds, derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. Level 3: Inputs are unobservable data points that are not corroborated by market data. The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of September 29, 2018 and December 31, 2017 : September 29, Quoted Significant Significant (In millions) 2018 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 49 $ 49 $ — $ — Bank time deposits 2 2 — — Investments in mutual funds and other similar instruments 12 12 — — Warrants 11 — 11 — Insurance contracts 122 — 122 — Derivative contracts 22 — 22 — Total Assets $ 218 $ 63 $ 155 $ — Liabilities Derivative contracts $ 185 $ — $ 185 $ — Contingent consideration 34 — — 34 Total Liabilities $ 219 $ — $ 185 $ 34 December 31, Quoted Significant Significant (In millions) 2017 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 22 $ 22 $ — $ — Bank time deposits 2 2 — — Investments in mutual funds and other similar instruments 13 13 — — Warrants 2 — 2 — Insurance contracts 116 — 116 — Derivative contracts 10 — 10 — Total Assets $ 165 $ 37 $ 128 $ — Liabilities Derivative contracts $ 139 $ — $ 139 $ — Contingent consideration 35 — — 35 Total Liabilities $ 174 $ — $ 139 $ 35 The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Nine Months Ended September 29, September 30, (In millions) 2018 2017 Contingent Consideration Beginning Balance $ 35 $ 6 Acquisitions 11 12 Payments (8 ) (1 ) Change in fair value included in earnings (4 ) 26 Ending Balance $ 34 $ 43 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. September 29, December 31, (In millions) 2018 2017 Notional Amount Interest rate swaps (described in Note 8) $ 3,100 $ 3,100 Cross-currency interest rate swaps - designated as net investment hedges 1,200 — Currency exchange contracts 2,991 2,921 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities September 29, December 31, September 29, December 31, (In millions) 2018 2017 2018 2017 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ — $ 180 $ 124 Cross-currency interest rate swaps (b) 8 — — — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (c) 14 10 5 15 Total Derivatives $ 22 $ 10 $ 185 $ 139 (a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities. (b) The fair value of the cross-currency interest rate swaps is included in the consolidated balance sheet under the caption other assets. (c) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (d) September 29, December 31, September 29, December 31, (In millions) 2018 2017 2018 2017 Long-term Obligations $ 3,240 $ 3,309 $ (143 ) $ (70 ) (d) Includes increases in the carrying amount of $34 million and $43 million at September 29, 2018 and December 31, 2017 , respectively, on discontinued hedging relationships. Gain (Loss) Recognized Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ (8 ) $ 2 $ (57 ) $ 12 Derivatives designated as hedging instruments - included in other expense, net 8 (4 ) 60 (9 ) Derivatives Designated as Cash Flow Hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to other expense, net (3 ) (3 ) (9 ) (9 ) Derivatives Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 50 (216 ) 250 (545 ) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 5 — 8 — Included in other expense, net 9 — 12 — Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of revenues 1 4 1 2 Included in other expense, net (2 ) 33 25 104 Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The company’s euro-denominated senior notes and cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K and Note 8 herein for additional information on the company's risk management objectives and strategies. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: September 29, 2018 December 31, 2017 Carrying Fair Carrying Fair (In millions) Value Value Value Value Notes Receivable $ 92 $ 97 $ 89 $ 93 Debt Obligations: Senior notes $ 18,323 $ 18,487 $ 20,024 $ 20,639 Commercial paper 429 429 960 960 Other 22 22 24 24 $ 18,774 $ 18,938 $ 21,008 $ 21,623 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 29, 2018
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 12 . Supplemental Cash Flow Information Nine Months Ended September 29, September 30, (In millions) 2018 2017 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 69 $ 61 Issuance of stock upon vesting of restricted stock units 167 120 Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: September 29, December 31, (In millions) 2018 2017 Cash and Cash Equivalents $ 1,098 $ 1,335 Restricted Cash Included in Other Current Assets 11 24 Restricted Cash Included in Other Assets 2 2 Cash, Cash Equivalents and Restricted Cash $ 1,111 $ 1,361 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs,

Restructuring and Other Costs, Net	9 Months Ended
	Sep. 29, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 13 . Restructuring and Other Costs (Income), Net Restructuring and other costs, net, in the first nine months of 2018 included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe; third-party transaction/integration costs related to the acquisitions of Patheon and Gatan; sales of inventories revalued at the date of acquisition; and gains from the favorable results of litigation. In the first nine months of 2018 , severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce. As of November 2, 2018 , the company has identified restructuring actions that will result in additional charges of approximately $95 million , primarily in 2018 and 2019 , which will be recorded when specified criteria are met, such as communication of benefit arrangements and abandonment of leased facilities. Third Quarter of 2018 During the third quarter of 2018 , the company recorded net restructuring and other income by segment as follows: (In millions) Cost of Revenues (Credits) Charges, Net Selling, General and Administrative (Credits) Charges, Net Restructuring and Other (Income) Costs, Net Total Life Sciences Solutions $ — $ (2 ) $ (47 ) $ (49 ) Analytical Instruments — 4 18 22 Specialty Diagnostics — — 1 1 Laboratory Products and Services (1 ) 5 1 5 Corporate — (11 ) — (11 ) $ (1 ) $ (4 ) $ (27 ) $ (32 ) The principal components of net restructuring and other costs by segment are as follows: Life Sciences Solutions In the third quarter of 2018 , the Life Sciences Solutions segment recorded $49 million of net restructuring and other income, principally for a gain on the resolution of litigation, partially offset by cash restructuring charges for employee severance and other costs associated with facility consolidations in the U.S. Analytical Instruments In the third quarter of 2018 , the Analytical Instruments segment recorded $22 million of net restructuring and other charges. The segment recorded $4 million of charges to selling, general, and administrative expenses for third-party transaction costs related to the acquisition of Gatan. The segment also recorded $18 million of restructuring and other costs, primarily for employee severance and other costs associated with facility consolidations in the U.S. and Europe. Laboratory Products and Services In the third quarter of 2018 , the Laboratory Products and Services segment recorded $5 million of net restructuring and other charges, principally charges to selling, general, and administrative expenses for third-party transaction/integration costs related to the acquisition of Patheon. Corporate In the third quarter of 2018 , the company recorded $11 million of net restructuring and other income from favorable results of product liability litigation. First Nine Months of 2018 During the first nine months of 2018 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ (2 ) $ (24 ) $ (26 ) Analytical Instruments 2 3 39 44 Specialty Diagnostics — — 5 5 Laboratory Products and Services 5 16 14 35 Corporate — (10 ) 1 (9 ) $ 7 $ 7 $ 35 $ 49 The principal components of net restructuring and other costs by segment are as follows: Life Sciences Solutions In the first nine months of 2018 , the Life Sciences Solutions segment recorded $26 million of net restructuring and other income, principally for a gain on the resolution of litigation, partially offset by charges for severance other costs associated with facility consolidations in the U.S. Analytical Instruments In the first nine months of 2018 , the Analytical Instruments segment recorded $44 million of net restructuring and other charges. The segment recorded net charges to cost of revenues of $2 million for the sales of inventory revalued at the date of acquisition; $3 million of net charges to selling, general, and administrative expense, principally third-party transaction costs related to the acquisition of Gatan; and $39 million of restructuring and other costs, primarily for employee severance and other costs associated with facility consolidations in the U.S. and Europe, as well as abandoned facilities costs associated with the remediation and closure of a manufacturing facility in the U.S. Specialty Diagnostics In the first nine months of 2018 , the Specialty Diagnostics segment recorded $5 million of net restructuring and other charges for severance and other costs associated with facility consolidations in the U.S. and Europe. Laboratory Products and Services In the first nine months of 2018 , the Laboratory Products and Services segment recorded $35 million of net restructuring and other charges. The segment recorded charges to cost of revenues of $5 million for the sales of inventory revalued at the date of acquisition, as well as $16 million of charges to selling, general, and administrative expenses for third-party transaction/integration costs related to the acquisition of Patheon. The segment also recorded $14 million of restructuring and other costs, primarily for employee severance, as well as hurricane response costs. Corporate In the first nine months of 2018 , the company recorded $9 million of net restructuring and other income, principally income from favorable results of product liability litigation, partially offset by charges for severance at its corporate operations. The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment of Excess Facilities Other (a) Total Balance at December 31, 2017 $ 30 $ 40 $ 6 $ 76 Costs incurred in 2018 (c) 47 29 13 89 Reserves reversed (b) (7 ) (6 ) (1 ) (14 ) Payments (29 ) (20 ) (13 ) (62 ) Currency translation (1 ) — — (1 ) Balance at September 29, 2018 $ 40 $ 43 $ 5 $ 88 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Represents reductions in cost of plans. (c) Excludes $40 million of income, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business. The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs, primarily through 2019 ; and abandoned-facility payments, over lease terms expiring through 2027 .

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 29, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The company recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (clinical trial logistics, pharmaceutical development and manufacturing services, asset management, diagnostic testing, training, service contracts, and field services including related time and materials) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated as inputs to measure progress. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. Payments from customers for most instruments, consumables and services are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g. extended service contracts), upon completion of the service (e.g. pharmaceutical development and manufacturing) or a mix of both.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2 ) and the ultimate loss from abandoning leases at facilities being exited (Note 13 ). Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, the FASB issued new guidance to align the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Under the new guidance, certain implementation costs that previously were required to be expensed will be capitalized and amortized over the term of the hosting arrangement. The company plans to adopt the guidance in the fourth quarter of 2018 prospectively to all implementation costs incurred after the date of adoption. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company expects to adopt the guidance when it is effective in 2020 using a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company expects to adopt the guidance when it is effective in 2020 with some items requiring a prospective method and others requiring a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In August 2018, the SEC adopted amendments to certain disclosure requirements effective November 5, 2018, including those relating to an interim presentation of the statement of shareholders’ equity. The adoption of this guidance is not expected to have a material impact on the company’s disclosures. In February 2018, the FASB issued new guidance to allow reclassifications from accumulated other comprehensive items (AOCI) to retained earnings for certain tax effects on items within AOCI resulting from the Tax Cuts and Jobs Act of 2017 (the Tax Act). The company adopted this guidance in January 2018 and recorded the reclassifications in the period of adoption. The balance sheet impact of adopting this guidance is included in the table below. This guidance only relates to the effects of the Tax Act. For all other tax law changes that have occurred or may occur in the future, the company reclassifies the tax effects to the consolidated statement of income on an item-by-item basis when the pre-tax item in AOCI is reclassified to income. In December 2017, the SEC staff issued guidance to address the application of accounting guidance in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act enacted on December 22, 2017. The company reported provisional amounts in its 2017 financial statements for certain income tax effects of the Tax Act for which a reasonable estimate could be determined but for which the accounting impact may change. For example, these estimates may be impacted by the need for further analysis and future clarification and guidance regarding available tax accounting methods and elections, earnings and profits computations and state tax conformity to federal changes. Adjustments to provisional amounts identified during the measurement period, which may be up to December 22, 2018, will be included as adjustments to Provision for Income Taxes in the period the amounts are determined (Note 6 ). In August 2017, the FASB issued new guidance to simplify the application of hedge accounting guidance. Among other things, the new guidance will permit more hedging strategies to qualify for hedge accounting, allow for additional time to perform an initial assessment of a hedge’s effectiveness, and permit a qualitative effectiveness test for certain hedges after initial qualification. The company adopted this guidance in January 2018. The balance sheet impact of adopting this guidance is included in the table below. In March 2017, the FASB issued new guidance intended to improve the presentation of net periodic pension cost and net periodic postretirement benefit cost. The new guidance requires the service cost component of net periodic cost be reported in the same line item(s) as other employee compensation costs and all other components of the net periodic cost be reported in the income statement below operating income. The company adopted this guidance on January 1, 2018 and applied the changes to the statement of income retrospectively. As a result of adoption of this guidance, the accompanying 2017 statement of income reflects the following changes from previously reported amounts: Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2017 2017 Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses) $ 2 $ 7 Decrease in Operating Income 2 7 Increase in Other Income (Expense) 2 7 In January 2017, the FASB issued new guidance clarifying the definition of a business and providing criteria to determine when an integrated set of assets and activities is not defined as a business. The new guidance requires such integrated sets to be defined as an asset (and not a business) if substantially all of the fair value of the gross assets acquired or disposed is concentrated in a single identifiable asset or a group of similar identifiable assets. The adoption of this guidance as of January 1, 2018 did not have a material impact on the company’s consolidated financial statements. In October 2016, the FASB issued new guidance eliminating the deferral of the tax effects of intra-entity asset transfers. The impact of this guidance in future periods will be dependent on the extent of future asset transfers which usually occur in connection with planning around acquisitions and other business structuring activities. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below. In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The guidance is effective for the company in 2020 using a modified retrospective method and early adoption is permitted. The company is currently evaluating the timing of adoption. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements. In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 and 2018, the FASB issued additional guidance and clarification. The company plans to adopt the guidance on January 1, 2019, using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods will not be restated. The company is currently evaluating the impact of this guidance by considering which practical expedients to elect, deploying a software tool to assist in the accounting calculations, surveying functional groups that oversee vendor relationships, and developing processes and controls to manage the changes in the lease guidance and gather information for the required disclosures. The company expects that assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities; however, the adoption of this guidance is not expected to have a material impact on the company’s results of operations or cash flows. The company’s future commitments under lease obligations are summarized in Note 10 to the consolidated financial statements for 2017 included in the company's Annual Report on Form 10-K, filed with the SEC. In January 2016, the FASB issued new guidance which affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. This guidance requires equity investments to be measured at fair value with subsequent changes recognized in net income, except for those accounted for under the equity method or requiring consolidation. The guidance also changes the accounting for investments without a readily determinable fair value and that do not qualify for the practical expedient permitted by the guidance to estimate fair value. The balance sheet impact of adopting this guidance as of January 1, 2018 is included in the table below. In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most previous revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. During 2016 and 2017, the FASB issued additional guidance and clarification, including the elimination of certain SEC Staff Guidance. The guidance is effective for the company in 2018. The company elected to adopt this guidance through application of the modified retrospective method by applying it to contracts that were not completed as of December 31, 2017 (in addition to new contracts in 2018). Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows: (In millions) December 31, Impact of Adopting New Revenue Guidance Impact of Adopting New Equity Investment Guidance Impact of Adopting New Intra-entity Tax Guidance Impact of Adopting New Hedge Accounting Guidance Impact of Adopting New Tax Effects on Items in AOCI Guidance January 1, 2018 Accounts Receivable, Less Allowances $ 3,879 $ (8 ) $ — $ — $ — $ — $ 3,871 Inventories 2,971 (252 ) — — — — 2,719 Other Current Assets 804 296 — — — — 1,100 Other Assets 1,227 — — (77 ) — — 1,150 Contract Liabilities — 805 — — — — 805 Deferred Revenue 719 (719 ) — — — — — Other Accrued Expenses 1,848 (153 ) — — — — 1,695 Deferred Income Taxes 2,766 — — (57 ) — 2 2,711 Other Long-term Liabilities 2,569 54 — — — — 2,623 Long-term Obligations 18,873 — — — (3 ) — 18,870 Retained Earnings 15,914 49 (1 ) (20 ) 3 87 16,032 Accumulated Other Comprehensive Items (2,003 ) — 1 — — (89 ) (2,091 ) Had the company continued to use the revenue recognition guidance in effect prior to 2018, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the three and nine months ended September 29, 2018 , from am ounts reported therein. However, inventories would have b een $329 million higher and other current assets would have been $339 million lower as of September 29, 2018 , primarily as a result of differences in the accounting for pharmaceutical development and manufacturing services under the new revenue guidance. Under the prior guidance, costs of these services were recorded in inventory while under the new guidance, costs are expensed as the manufacturing service is performed and the company's rights to consideration are recorded as contract assets and included in other current assets.
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Acquisitions (Policies)

Acquisitions (Policies)	9 Months Ended
	Sep. 29, 2018
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 29, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract with Customer, Asset and Liability [Table Text Block]	Contract asset and liability balances are as follows: September 29, January 1, (In millions) 2018 2018 Current Contract Assets, Net $ 462 $ 396 Current Contract Liabilities 797 805 Noncurrent Contract Liabilities 349 302
Warranty Obligations [Table Text Block]	Warranty Obligations The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows: Nine Months Ended September 29, September 30, (In millions) 2018 2017 Beginning Balance $ 87 $ 78 Provision charged to income 89 76 Usage (80 ) (75 ) Acquisitions — 1 Adjustments to previously provided warranties, net (3 ) (2 ) Currency translation (2 ) 3 Ending Balance $ 91 $ 81
Inventories [Table Text Block]	Inventories The components of inventories are as follows: September 29, December 31, (In millions) 2018 2017 Raw Materials $ 807 $ 708 Work in Process 433 505 Finished Goods 1,742 1,758 Inventories $ 2,982 $ 2,971
Property, Plant and Equipment [Table Text Block]	Property, Plant and Equipment Property, plant and equipment consists of the following: September 29, December 31, (In millions) 2018 2017 Land $ 392 $ 401 Buildings and Improvements 1,677 1,662 Machinery, Equipment and Leasehold Improvements 4,536 4,276 Property, Plant and Equipment, at Cost 6,605 6,339 Less: Accumulated Depreciation and Amortization 2,627 2,292 Property, Plant and Equipment, Net $ 3,978 $ 4,047
Finite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at September 29, 2018 Balance at December 31, 2017 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite Lived: Customer relationships $ 17,092 $ (6,592 ) $ 10,500 $ 17,356 $ (5,902 ) $ 11,454 Product technology 6,003 (3,143 ) 2,860 6,046 (2,811 ) 3,235 Tradenames 1,512 (920 ) 592 1,538 (817 ) 721 Other 33 (33 ) — 34 (34 ) — 24,640 (10,688 ) 13,952 24,974 (9,564 ) 15,410 Indefinite Lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 In-process research and development 32 N/A 32 39 N/A 39 1,267 N/A 1,267 1,274 N/A 1,274 Acquisition-related Intangible Assets $ 25,907 $ (10,688 ) $ 15,219 $ 26,248 $ (9,564 ) $ 16,684
Indefinite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at September 29, 2018 Balance at December 31, 2017 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite Lived: Customer relationships $ 17,092 $ (6,592 ) $ 10,500 $ 17,356 $ (5,902 ) $ 11,454 Product technology 6,003 (3,143 ) 2,860 6,046 (2,811 ) 3,235 Tradenames 1,512 (920 ) 592 1,538 (817 ) 721 Other 33 (33 ) — 34 (34 ) — 24,640 (10,688 ) 13,952 24,974 (9,564 ) 15,410 Indefinite Lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 In-process research and development 32 N/A 32 39 N/A 39 1,267 N/A 1,267 1,274 N/A 1,274 Acquisition-related Intangible Assets $ 25,907 $ (10,688 ) $ 15,219 $ 26,248 $ (9,564 ) $ 16,684
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Adoption of new guidance that became effective on January 1, 2018, impacted the company's Consolidated Balance Sheet as follows: (In millions) December 31, Impact of Adopting New Revenue Guidance Impact of Adopting New Equity Investment Guidance Impact of Adopting New Intra-entity Tax Guidance Impact of Adopting New Hedge Accounting Guidance Impact of Adopting New Tax Effects on Items in AOCI Guidance January 1, 2018 Accounts Receivable, Less Allowances $ 3,879 $ (8 ) $ — $ — $ — $ — $ 3,871 Inventories 2,971 (252 ) — — — — 2,719 Other Current Assets 804 296 — — — — 1,100 Other Assets 1,227 — — (77 ) — — 1,150 Contract Liabilities — 805 — — — — 805 Deferred Revenue 719 (719 ) — — — — — Other Accrued Expenses 1,848 (153 ) — — — — 1,695 Deferred Income Taxes 2,766 — — (57 ) — 2 2,711 Other Long-term Liabilities 2,569 54 — — — — 2,623 Long-term Obligations 18,873 — — — (3 ) — 18,870 Retained Earnings 15,914 49 (1 ) (20 ) 3 87 16,032 Accumulated Other Comprehensive Items (2,003 ) — 1 — — (89 ) (2,091 ) Three Months Ended Nine Months Ended September 30, September 30, (In millions) 2017 2017 Increase in Total Costs and Operating Expenses (principally Selling, General and Administrative Expenses) $ 2 $ 7 Decrease in Operating Income 2 7 Increase in Other Income (Expense) 2 7

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 29, 2018
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information provides the effect of the company's acquisition of Patheon as if the acquisition had occurred on January 1, 2016: Three Months Ended Nine Months Ended September 30, September 30, (In millions except per share amounts) 2017 2017 Revenues $ 5,393 $ 16,076 Net Income $ 522 $ 1,671

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 29, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenue Revenue by type is as follows: Three Months Ended Nine Months Ended September 29, September 29, (In millions) 2018 2018 Revenues Consumables 3,056 $ 9,345 Instruments 1,515 4,462 Services 1,349 4,044 Consolidated revenues $ 5,920 $ 17,851 Revenue by geographic region is as follows: Three Months Ended Nine Months Ended September 29, September 29, (In millions) 2018 2018 Revenues North America $ 3,030 $ 8,975 Europe 1,454 4,521 Asia-Pacific 1,251 3,809 Other regions 185 546 Consolidated revenues $ 5,920 $ 17,851

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	9 Months Ended
	Sep. 29, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Revenues Life Sciences Solutions $ 1,504 $ 1,382 $ 4,572 $ 4,150 Analytical Instruments 1,333 1,189 3,901 3,407 Specialty Diagnostics 894 844 2,773 2,572 Laboratory Products and Services 2,470 1,933 7,433 5,424 Eliminations (281 ) (232 ) (828 ) (682 ) Consolidated revenues 5,920 5,116 17,851 14,871 Segment Income (a) Life Sciences Solutions 495 452 1,534 1,333 Analytical Instruments 294 257 831 681 Specialty Diagnostics 223 218 719 685 Laboratory Products and Services 299 243 916 704 Subtotal reportable segments (a) 1,311 1,170 4,000 3,403 Cost of revenues credits (charges), net 1 (45 ) (7 ) (77 ) Selling, general and administrative credits (charges), net 4 (37 ) (7 ) (75 ) Restructuring and other income (costs), net 27 (49 ) (35 ) (95 ) Amortization of acquisition-related intangible assets (431 ) (405 ) (1,316 ) (1,153 ) Consolidated operating income 912 634 2,635 2,003 Other expense, net (b) (102 ) (154 ) (385 ) (394 ) Income from continuing operations before income taxes $ 810 $ 480 $ 2,250 $ 1,609 Depreciation Life Sciences Solutions $ 29 $ 32 $ 89 $ 97 Analytical Instruments 18 17 53 51 Specialty Diagnostics 19 19 56 54 Laboratory Products and Services 66 44 195 104 Consolidated depreciation $ 132 $ 112 $ 393 $ 306 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Revenues Life Sciences Solutions $ 1,504 $ 1,382 $ 4,572 $ 4,150 Analytical Instruments 1,333 1,189 3,901 3,407 Specialty Diagnostics 894 844 2,773 2,572 Laboratory Products and Services 2,470 1,933 7,433 5,424 Eliminations (281 ) (232 ) (828 ) (682 ) Consolidated revenues 5,920 5,116 17,851 14,871 Segment Income (a) Life Sciences Solutions 495 452 1,534 1,333 Analytical Instruments 294 257 831 681 Specialty Diagnostics 223 218 719 685 Laboratory Products and Services 299 243 916 704 Subtotal reportable segments (a) 1,311 1,170 4,000 3,403 Cost of revenues credits (charges), net 1 (45 ) (7 ) (77 ) Selling, general and administrative credits (charges), net 4 (37 ) (7 ) (75 ) Restructuring and other income (costs), net 27 (49 ) (35 ) (95 ) Amortization of acquisition-related intangible assets (431 ) (405 ) (1,316 ) (1,153 ) Consolidated operating income 912 634 2,635 2,003 Other expense, net (b) (102 ) (154 ) (385 ) (394 ) Income from continuing operations before income taxes $ 810 $ 480 $ 2,250 $ 1,609 Depreciation Life Sciences Solutions $ 29 $ 32 $ 89 $ 97 Analytical Instruments 18 17 53 51 Specialty Diagnostics 19 19 56 54 Laboratory Products and Services 66 44 195 104 Consolidated depreciation $ 132 $ 112 $ 393 $ 306 (a) Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. (b) The company does not allocate other expense, net to its segments.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Revenues (c) United States $ 2,918 $ 2,454 $ 8,588 $ 7,315 China 629 523 1,818 1,476 Other 2,373 2,139 7,445 6,080 Consolidated revenues $ 5,920 $ 5,116 $ 17,851 $ 14,871 (c) Revenues are attributed to countries based on customer location.

Other Expense, Net (Tables)

Other Expense, Net (Tables)	9 Months Ended
	Sep. 29, 2018
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	The components of other expense, net, in the accompanying statement of income are as follows: Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Interest Income $ 41 $ 25 $ 92 $ 61 Interest Expense (162 ) (157 ) (495 ) (426 ) Other Items, Net 19 (22 ) 18 (29 ) Other Expense, Net $ (102 ) $ (154 ) $ (385 ) $ (394 )

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 29, 2018
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine Months Ended September 29, September 30, (In millions) 2018 2017 Statutory Federal Income Tax Rate 21 % 35 % Provision for Income Taxes at Statutory Rate $ 473 $ 563 Increases (Decreases) Resulting From: Foreign rate differential (177 ) (287 ) Foreign exchange loss on inter-company debt refinancing — (237 ) Income tax credits (183 ) (101 ) Global intangible low-taxed income 124 — Foreign-derived intangible income (34 ) — Withholding taxes — 49 Singapore tax holiday (29 ) (17 ) Impact of change in tax laws and apportionment on deferred taxes 14 (60 ) Transition tax and other initial impacts of U.S. tax reform 117 — (Reversal of) provision for tax reserves, net (49 ) 13 Excess tax benefits from stock options and restricted stock units (59 ) (51 ) Valuation allowance — 50 Other, net 13 (11 ) Provision for (benefit from) income taxes $ 210 $ (89 )
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2018 Balance at beginning of year $ 1,409 Reductions due to acquisitions (9 ) Additions for tax positions of current year 5 Additions for tax positions of prior years 88 Reductions for tax positions of prior years (69 ) Settlements (52 ) Balance at end of period $ 1,372

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Sep. 29, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions except per share amounts) 2018 2017 2018 2017 Income from Continuing Operations $ 709 $ 534 $ 2,040 $ 1,698 Loss from Discontinued Operations — — — (1 ) Net Income $ 709 $ 534 $ 2,040 $ 1,697 Basic Weighted Average Shares 402 396 402 392 Plus Effect of: Stock options and restricted units 4 4 4 4 Diluted Weighted Average Shares 406 400 406 396 Basic Earnings per Share: Continuing operations $ 1.76 $ 1.35 $ 5.07 $ 4.33 Discontinued operations — — — — Basic Earnings per Share $ 1.76 $ 1.35 $ 5.07 $ 4.32 Diluted Earnings per Share: Continuing operations $ 1.75 $ 1.34 $ 5.03 $ 4.29 Discontinued operations — — — — Diluted Earnings per Share $ 1.75 $ 1.34 $ 5.03 $ 4.29 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares 2 2 2 2

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	9 Months Ended
	Sep. 29, 2018
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at September 29, September 29, December 31, (Dollars in millions) 2018 2018 2017 Commercial Paper — % $ 429 $ 960 Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated) — 721 2.15% 3-Year Senior Notes, Due 12/14/2018 — 450 2.40% 5-Year Senior Notes, Due 2/1/2019 — 900 Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) 0.10 % 581 600 6.00% 10-Year Senior Notes, Due 3/1/2020 2.98 % 750 750 4.70% 10-Year Senior Notes, Due 5/1/2020 4.23 % 300 300 Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) 0.16 % 696 — 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) 1.62 % 493 510 5.00% 10-Year Senior Notes, Due 1/15/2021 3.25 % 400 400 4.50% 10-Year Senior Notes, Due 3/1/2021 7.06 % 1,000 1,000 3.60% 10-Year Senior Notes, Due 8/15/2021 6.83 % 1,100 1,100 3.30% 7-Year Senior Notes, Due 2/15/2022 3.42 % 800 800 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) 2.28 % 581 600 3.15% 10-Year Senior Notes, Due 1/15/2023 3.30 % 800 800 3.00% 7-Year Senior Notes, Due 4/15/2023 7.11 % 1,000 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 4.16 % 1,000 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,160 1,201 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 743 768 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 812 840 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 581 600 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 696 721 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 812 840 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 812 840 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 Other 22 24 Total Borrowings at Par Value 19,018 21,175 Fair Value Hedge Accounting Adjustments (143 ) (70 ) Unamortized Discount, Net (16 ) (2 ) Unamortized Debt Issuance Costs (85 ) (95 ) Total Borrowings at Carrying Value 18,774 21,008 Less: Short-term Obligations and Current Maturities 1,014 2,135 Long-term Obligations $ 17,760 $ 18,873
Schedule of Derivative Instruments [Table Text Block]	The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at September 29, 2018 : Aggregate Notional Amount Pay Rate as of (Dollars in millions) Pay Rate September 29, Receive Rate 4.50% Senior Notes due 2021 (a) 1,000 1-month LIBOR + 3.4420% 5.5458 % 4.50 % 3.60% Senior Notes due 2021 1,100 1-month LIBOR + 2.5150% 4.6734 % 3.60 % 3.00% Senior Notes due 2023 (a) 1,000 1-month LIBOR + 1.7640% 3.9224 % 3.00 %

Comprehensive Income and Shar_2

Comprehensive Income and Shareholders Equity (Tables)	9 Months Ended
	Sep. 29, 2018
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Unrealized Pension and Total Balance at December 31, 2017 $ (1,755 ) $ (1 ) $ (50 ) $ (197 ) $ (2,003 ) Cumulative effect of accounting changes (Note 1) (54 ) 1 (11 ) (24 ) (88 ) Other comprehensive income (loss) before reclassifications (447 ) — — 3 (444 ) Amounts reclassified from accumulated other comprehensive items — — 6 10 16 Net other comprehensive items (447 ) — 6 13 (428 ) Balance at September 29, 2018 $ (2,256 ) $ — $ (55 ) $ (208 ) $ (2,519 )

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 29, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of September 29, 2018 and December 31, 2017 : September 29, Quoted Significant Significant (In millions) 2018 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 49 $ 49 $ — $ — Bank time deposits 2 2 — — Investments in mutual funds and other similar instruments 12 12 — — Warrants 11 — 11 — Insurance contracts 122 — 122 — Derivative contracts 22 — 22 — Total Assets $ 218 $ 63 $ 155 $ — Liabilities Derivative contracts $ 185 $ — $ 185 $ — Contingent consideration 34 — — 34 Total Liabilities $ 219 $ — $ 185 $ 34 December 31, Quoted Significant Significant (In millions) 2017 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 22 $ 22 $ — $ — Bank time deposits 2 2 — — Investments in mutual funds and other similar instruments 13 13 — — Warrants 2 — 2 — Insurance contracts 116 — 116 — Derivative contracts 10 — 10 — Total Assets $ 165 $ 37 $ 128 $ — Liabilities Derivative contracts $ 139 $ — $ 139 $ — Contingent consideration 35 — — 35 Total Liabilities $ 174 $ — $ 139 $ 35
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration. Nine Months Ended September 29, September 30, (In millions) 2018 2017 Contingent Consideration Beginning Balance $ 35 $ 6 Acquisitions 11 12 Payments (8 ) (1 ) Change in fair value included in earnings (4 ) 26 Ending Balance $ 34 $ 43
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. September 29, December 31, (In millions) 2018 2017 Notional Amount Interest rate swaps (described in Note 8) $ 3,100 $ 3,100 Cross-currency interest rate swaps - designated as net investment hedges 1,200 — Currency exchange contracts 2,991 2,921
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities September 29, December 31, September 29, December 31, (In millions) 2018 2017 2018 2017 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ — $ 180 $ 124 Cross-currency interest rate swaps (b) 8 — — — Derivatives Not Designated as Hedging Instruments Currency exchange contracts (c) 14 10 5 15 Total Derivatives $ 22 $ 10 $ 185 $ 139 (a) The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities. (b) The fair value of the cross-currency interest rate swaps is included in the consolidated balance sheet under the caption other assets. (c) The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (d) September 29, December 31, September 29, December 31, (In millions) 2018 2017 2018 2017 Long-term Obligations $ 3,240 $ 3,309 $ (143 ) $ (70 ) (d) Includes increases in the carrying amount of $34 million and $43 million at September 29, 2018 and December 31, 2017 , respectively, on discontinued hedging relationships
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended Nine Months Ended September 29, September 30, September 29, September 30, (In millions) 2018 2017 2018 2017 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other expense, net $ (8 ) $ 2 $ (57 ) $ 12 Derivatives designated as hedging instruments - included in other expense, net 8 (4 ) 60 (9 ) Derivatives Designated as Cash Flow Hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to other expense, net (3 ) (3 ) (9 ) (9 ) Derivatives Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 50 (216 ) 250 (545 ) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 5 — 8 — Included in other expense, net 9 — 12 — Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of revenues 1 4 1 2 Included in other expense, net (2 ) 33 25 104
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: September 29, 2018 December 31, 2017 Carrying Fair Carrying Fair (In millions) Value Value Value Value Notes Receivable $ 92 $ 97 $ 89 $ 93 Debt Obligations: Senior notes $ 18,323 $ 18,487 $ 20,024 $ 20,639 Commercial paper 429 429 960 960 Other 22 22 24 24 $ 18,774 $ 18,938 $ 21,008 $ 21,623 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s notes receivable and debt obligations are as follows: September 29, 2018 December 31, 2017 Carrying Fair Carrying Fair (In millions) Value Value Value Value Notes Receivable $ 92 $ 97 $ 89 $ 93 Debt Obligations: Senior notes $ 18,323 $ 18,487 $ 20,024 $ 20,639 Commercial paper 429 429 960 960 Other 22 22 24 24 $ 18,774 $ 18,938 $ 21,008 $ 21,623 The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 29, 2018
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended September 29, September 30, (In millions) 2018 2017 Non-cash Investing and Financing Activities Declared but unpaid dividends $ 69 $ 61 Issuance of stock upon vesting of restricted stock units 167 120
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: September 29, December 31, (In millions) 2018 2017 Cash and Cash Equivalents $ 1,098 $ 1,335 Restricted Cash Included in Other Current Assets 11 24 Restricted Cash Included in Other Assets 2 2 Cash, Cash Equivalents and Restricted Cash $ 1,111 $ 1,361

Restructuring and Other Costs_2

Restructuring and Other Costs, Net (Tables)	9 Months Ended
	Sep. 29, 2018
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the third quarter of 2018 , the company recorded net restructuring and other income by segment as follows: (In millions) Cost of Revenues (Credits) Charges, Net Selling, General and Administrative (Credits) Charges, Net Restructuring and Other (Income) Costs, Net Total Life Sciences Solutions $ — $ (2 ) $ (47 ) $ (49 ) Analytical Instruments — 4 18 22 Specialty Diagnostics — — 1 1 Laboratory Products and Services (1 ) 5 1 5 Corporate — (11 ) — (11 ) $ (1 ) $ (4 ) $ (27 ) $ (32 ) During the first nine months of 2018 , the company recorded net restructuring and other costs by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ (2 ) $ (24 ) $ (26 ) Analytical Instruments 2 3 39 44 Specialty Diagnostics — — 5 5 Laboratory Products and Services 5 16 14 35 Corporate — (10 ) 1 (9 ) $ 7 $ 7 $ 35 $ 49
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Severance Abandonment of Excess Facilities Other (a) Total Balance at December 31, 2017 $ 30 $ 40 $ 6 $ 76 Costs incurred in 2018 (c) 47 29 13 89 Reserves reversed (b) (7 ) (6 ) (1 ) (14 ) Payments (29 ) (20 ) (13 ) (62 ) Currency translation (1 ) — — (1 ) Balance at September 29, 2018 $ 40 $ 43 $ 5 $ 88 (a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Represents reductions in cost of plans. (c) Excludes $40 million of income, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2018	Jan. 01, 2018	Dec. 31, 2017
Contract with Customer, Asset and Liability [Abstract]
Current Contract Assets, Net	$ 462	$ 396
Current Contract Liabilities	797	805	$ 0
Noncurrent Contract Liability	349	$ 302
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 591

Warranty Obligations (Details)

Warranty Obligations (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017
Warranty Obligations [Roll Forward]
Beginning Balance	$ 87	$ 78
Provision charged to income	89	76
Usage	(80)	(75)
Acquisitions		1
Adjustments to previously provided warranties, net	(3)	(2)
Currency translation	(2)	3
Ending Balance	$ 91	$ 81

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 29, 2018	Jan. 01, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw Materials	$ 807		$ 708
Work in Process	433		505
Finished Goods	1,742		1,758
Inventories	$ 2,982	$ 2,719	$ 2,971

Property, Plant and Equipment (

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$ 6,605	$ 6,339
Less: Accumulated Depreciation and Amortization	2,627	2,292
Property, Plant and Equipment, Net	3,978	4,047
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	392	401
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	1,677	1,662
Machinery, Equipment and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$ 4,536	$ 4,276

Acquisition-related Intangible

Acquisition-related Intangible Assets (Details) - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	$ 24,640	$ 24,974
Accumulated Amortization	(10,688)	(9,564)
Definite-Lived Intangible Assets, Net	13,952	15,410
Indefinite-Lived Intangible Assets	1,267	1,274
Acquisition-related Intangible Assets, Gross	25,907	26,248
Acquisition-related Intangible Assets, net of Accumulated Amortization	15,219	16,684
Tradenames [Member]
Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,235	1,235
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	32	39
Customer Relationships [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	17,092	17,356
Accumulated Amortization	(6,592)	(5,902)
Definite-Lived Intangible Assets, Net	10,500	11,454
Product Technology [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	6,003	6,046
Accumulated Amortization	(3,143)	(2,811)
Definite-Lived Intangible Assets, Net	2,860	3,235
Tradenames [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	1,512	1,538
Accumulated Amortization	(920)	(817)
Definite-Lived Intangible Assets, Net	592	721
Other Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	33	34
Accumulated Amortization	(33)	(34)
Definite-Lived Intangible Assets, Net	$ 0	$ 0

Recent Accounting Pronouncement

Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in Total Costs and Operating Expenses (principally SG&A Expenses)	$ 5,008	$ 4,482	$ 15,216	$ 12,868
Decrease in Operating Income	(912)	(634)	(2,635)	(2,003)
Increase in Other Income (Expense)	(102)	(154)	(385)	(394)
Accounts receivable, less allowances	3,852		3,852		$ 3,871	$ 3,879
Inventories	2,982		2,982		2,719	2,971
Other current assets	1,229		1,229		1,100	804
Other Assets	1,173		1,173		1,150	1,227
Contract liabilities	797		797		805	0
Deferred Revenue	0		0		0	719
Other accrued expenses	1,224		1,224		1,695	1,848
Deferred Income Taxes	2,550		2,550		2,711	2,766
Other Long-term Liabilities	2,682		2,682		2,623	2,569
Long-term Obligations	17,760		17,760		18,870	18,873
Retained earnings	17,866		17,866		16,032	15,914
Accumulated other comprehensive items	(2,519)		(2,519)		(2,091)	$ (2,003)
Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in Total Costs and Operating Expenses (principally SG&A Expenses)		2		7
Decrease in Operating Income		2		7
Increase in Other Income (Expense)		$ 2		$ 7
Accounting Standards Update 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings					(1)
Accumulated other comprehensive items					1
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other Assets					(77)
Deferred Income Taxes					(57)
Retained earnings					(20)
Accounting Standards Update 2017-12 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term Obligations					(3)
Retained earnings					3
Accounting Standard Update 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred Income Taxes					2
Retained earnings					87
Accumulated other comprehensive items					(89)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	(329)		(329)
Other current assets	$ 339		$ 339
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts receivable, less allowances					(8)
Inventories					(252)
Other current assets					296
Contract liabilities					805
Deferred Revenue					(719)
Other accrued expenses					(153)
Other Long-term Liabilities					54
Retained earnings					$ 49

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) - USD ($) $ in Millions	Oct. 25, 2018	Dec. 31, 2018	Sep. 29, 2018	Dec. 31, 2017
Other [Member]
Purchase Price
Total Purchase Price			$ 65
Advanced Bioprocessing business [Member]
Net Assets Acquired [Abstract]
Revenue Reported by Acquired Entity				$ 100
Scenario, Forecast [Member] | Gatan, Inc. [Member]
Purchase Price
Cash paid		$ 925
Subsequent Event [Member] | Advanced Bioprocessing business [Member]
Purchase Price
Cash paid	$ 477

Acquisition Pro Forma Results (

Acquisition Pro Forma Results (Details) - Patheon N.V. [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue	$ 5,393	$ 16,076
Business Acquisition, Pro Forma Net Income (Loss)	$ 522	1,671
Acquisition-related Costs [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Net Income (Loss)		42
Costs to Conform Accounting Policies [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Net Income (Loss)		33
Restructuring Charges [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Net Income (Loss)		18
Deferred Revenue [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Net Income (Loss)		18
Fair Value Adjustment to Inventory [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Net Income (Loss)		$ 15

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 5,920	$ 5,116	$ 17,851	$ 14,871
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,030		8,975
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,454		4,521
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,251		3,809
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	185		546
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,056		9,345
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,515		4,462
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 1,349	$ 884	$ 4,044	$ 2,239

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Sep. 29, 2018USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 5,120
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-09-30
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	90.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Business Segment Information (D

Business Segment Information (Details) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 29, 2018USD ($)Segment	Sep. 30, 2017USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments | Segment				4
Revenues		$ 5,920	$ 5,116	$ 17,851	$ 14,871
Cost of revenues credits (charges), net		1		(7)
Selling, general and administrative credits (charges), net		4		(7)
Restructuring and other costs, net		27	(49)	(35)	(95)
Operating Income		912	634	2,635	2,003
Other expense, net		(102)	(154)	(385)	(394)
Income from Continuing Operations Before Income Taxes		810	480	2,250	1,609
Depreciation		132	112	393	306
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative credits (charges), net		2		2
Restructuring and other costs, net		47		24
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Cost of revenues credits (charges), net				(2)
Selling, general and administrative credits (charges), net		(4)		(3)
Restructuring and other costs, net		(18)		(39)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Restructuring and other costs, net		(1)		(5)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues credits (charges), net		1		(5)
Selling, general and administrative credits (charges), net		(5)		(16)
Restructuring and other costs, net		(1)		(14)
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	[1]	1,311	1,170	4,000	3,403
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues		1,504	1,382	4,572	4,150
Operating Income	[1]	495	452	1,534	1,333
Depreciation		29	32	89	97
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues		1,333	1,189	3,901	3,407
Operating Income	[1]	294	257	831	681
Depreciation		18	17	53	51
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues		894	844	2,773	2,572
Operating Income	[1]	223	218	719	685
Depreciation		19	19	56	54
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues		2,470	1,933	7,433	5,424
Operating Income	[1]	299	243	916	704
Depreciation		66	44	195	104
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues		(281)	(232)	(828)	(682)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues credits (charges), net		1	(45)	(7)	(77)
Selling, general and administrative credits (charges), net		4	(37)	(7)	(75)
Restructuring and other costs, net		27	(49)	(35)	(95)
Amortization of acquisition-related intangible assets		$ (431)	$ (405)	$ (1,316)	$ (1,153)
[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 5,920	$ 5,116	$ 17,851	$ 14,871
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	2,918	2,454	8,588	7,315
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	629	523	1,818	1,476
All Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 2,373	$ 2,139	$ 7,445	$ 6,080
[1]	Revenues are attributed to countries based on customer location.

Other Expense, Net (Details)

Other Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Other Income and Expenses [Abstract]
Interest Income	$ 41	$ 25	$ 92	$ 61
Interest Expense	(162)	(157)	(495)	(426)
Other Items, Net	19	(22)	18	(29)
Other Expense, Net	$ (102)	$ (154)	$ (385)	$ (394)

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 29, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate				21.00%	35.00%
Provision for Income Taxes at Statutory Rate				$ 473	$ 563
Foreign rate differential				(177)	(287)
Foreign exchange loss on inter-company debt refinancing					(237)
Income tax credits				(183)	(101)
Global intangible low-taxed income				124
Foreign-derived intangible income				34
Withholding taxes					49
Singapore tax holiday				(29)	(17)
Impact of change in tax laws and apportionment on deferred taxes				14	(60)
Transition tax and other initial impacts of U.S. tax reform	$ 47	$ 70		117
(Reversal of) provision for tax reserves, net		(49)		(49)	13
Excess tax benefits from stock options and restricted stock units				(59)	(51)
Valuation allowance					50
Other, net				13	(11)
Provision for (benefit from) income taxes	$ 101		$ (54)	$ 210	$ (89)
Tax Cuts And Jobs Act of 2017, Income Tax Expense (Benefit)		$ 21
Singapore
Income Tax Holiday [Line Items]
Income Tax Holiday, Termination Date				12/31/2026
Effective Income Tax Rate Reconciliation, Tax Holiday, Percent				1.30%	1.10%
Income Tax Holiday, Income Tax Benefits Per Share				$ 0.07	$ 0.04

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	9 Months Ended
	Sep. 29, 2018USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of year	$ 1,409
Reductions due to acquisitions	(9)
Additions for tax positions of current year	5
Additions for tax positions of prior years	88
Reductions for tax positions of prior years	(69)
Settlements	(52)
Balance at end of year	$ 1,372

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Income from Continuing Operations	$ 709	$ 534	$ 2,040	$ 1,698
Loss from Discontinued Operations	0	0	0	(1)
Net Income	$ 709	$ 534	$ 2,040	$ 1,697
Basic Weighted Average Shares	402	396	402	392
Effect of Stock Options and Restricted Units	4	4	4	4
Diluted Weighted Average Shares	406	400	406	396
Basic Earnings per Share:
Continuing operations (in dollars per share)	$ 1.76	$ 1.35	$ 5.07	$ 4.33
Discontinued operations (in dollars per share)	0	0	0	0
Basic Earnings Per Share (in dollars per share)	1.76	1.35	5.07	4.32
Diluted Earnings per Share:
Continuing operations (in dollars per share)	1.75	1.34	5.03	4.29
Discontinued operations (in dollars per share)	0	0	0	0
Diluted Earnings Per Share (in dollars per share)	$ 1.75	$ 1.34	$ 5.03	$ 4.29
Employee Stock Option [Member]
Diluted Earnings per Share:
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	2	2	2	2

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2018	Jan. 01, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total Borrowings at Par Value	$ 19,018		$ 21,175
Fair Value Hedge Accounting Adjustments	(143)		(70)
Unamortized Discount, Net	(16)		(2)
Unamortized Debt Issuance Costs	(85)		(95)
Total Borrowings at Carrying Value	18,774		21,008
Less: Short-term Obligations and Current Maturities	1,014		2,135
Long-term Obligations	$ 17,760	$ 18,870	18,873
Commercial Paper Programs [Member]
Debt Instrument [Line Items]
Effective Interest Rate	0.00%
Total Borrowings at Par Value	$ 429		960
Total Borrowings at Carrying Value	429		960
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value	$ 18,323		20,024
Debt Instrument, Call Feature	Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest.
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 8/9/2018 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Aug. 9, 2018
Total Borrowings at Par Value			721
Senior Notes [Member] | 2.15% 3-Year Senior Notes, Due 12/14/2018 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	Dec. 14, 2018
Total Borrowings at Par Value			450
Senior Notes [Member] | 2.40% 5-Year Senior Notes, Due 2/1/2019 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.40%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Feb. 1, 2019
Total Borrowings at Par Value			900
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Jul. 24, 2019
Effective Interest Rate	0.10%
Total Borrowings at Par Value	$ 581		600
Senior Notes [Member] | 6.00% 10-Year Senior Notes, Due 3/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	6.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 1, 2020
Effective Interest Rate	2.98%
Total Borrowings at Par Value	$ 750		750
Senior Notes [Member] | 4.70% 10-Year Senior Notes, Due 5/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.70%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	May 1, 2020
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 300		300
Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated) [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Aug. 7, 2020
Effective Interest Rate	0.16%
Total Borrowings at Par Value	$ 696
Senior Notes [Member] | 1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.50%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	Dec. 1, 2020
Effective Interest Rate	1.62%
Total Borrowings at Par Value	$ 493		510
Senior Notes [Member] | 5.00% 10-Year Senior Notes, Due 1/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Jan. 15, 2021
Effective Interest Rate	3.25%
Total Borrowings at Par Value	$ 400		400
Senior Notes [Member] | 4.50% 10-Year Senior Notes, Due 3/1/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.50%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 1, 2021
Effective Interest Rate	7.06%
Total Borrowings at Par Value	$ 1,000		1,000
Senior Notes [Member] | 3.60% 10-Year Senior Notes, Due 8/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2021
Effective Interest Rate	6.83%
Total Borrowings at Par Value	$ 1,100		1,100
Senior Notes [Member] | 3.30% 7-Year Senior Notes, Due 2/15/2022 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.30%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Feb. 15, 2022
Effective Interest Rate	3.42%
Total Borrowings at Par Value	$ 800		800
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.15%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Jul. 21, 2022
Effective Interest Rate	2.28%
Total Borrowings at Par Value	$ 581		600
Senior Notes [Member] | 3.15% 10-Year Senior Notes, Due 1/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Jan. 15, 2023
Effective Interest Rate	3.30%
Total Borrowings at Par Value	$ 800		800
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.00%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	Apr. 15, 2023
Effective Interest Rate	7.11%
Total Borrowings at Par Value	$ 1,000		1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Feb. 1, 2024
Effective Interest Rate	4.16%
Total Borrowings at Par Value	$ 1,000		1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	0.75%
Debt Instrument, Term	8 years
Debt Instrument, Maturity Date	Sep. 12, 2024
Effective Interest Rate	0.94%
Total Borrowings at Par Value	$ 1,160		1,201
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Apr. 15, 2025
Effective Interest Rate	2.10%
Total Borrowings at Par Value	$ 743		768
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.65%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Effective Interest Rate	3.77%
Total Borrowings at Par Value	$ 350		350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.40%
Debt Instrument, Term	8 years 6 months
Debt Instrument, Maturity Date	Jan. 23, 2026
Effective Interest Rate	1.53%
Total Borrowings at Par Value	$ 812		840
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.95%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Sep. 19, 2026
Effective Interest Rate	3.19%
Total Borrowings at Par Value	$ 1,200		1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.45%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Mar. 16, 2027
Effective Interest Rate	1.66%
Total Borrowings at Par Value	$ 581		600
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	Aug. 15, 2027
Effective Interest Rate	3.39%
Total Borrowings at Par Value	$ 750		750
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.375%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Sep. 12, 2028
Effective Interest Rate	1.46%
Total Borrowings at Par Value	$ 696		721
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.95%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Jul. 24, 2029
Effective Interest Rate	2.08%
Total Borrowings at Par Value	$ 812		840
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.875%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Jul. 24, 2037
Effective Interest Rate	2.94%
Total Borrowings at Par Value	$ 812		840
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Feb. 1, 2044
Effective Interest Rate	5.37%
Total Borrowings at Par Value	$ 400		400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.10%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Aug. 15, 2047
Effective Interest Rate	4.23%
Total Borrowings at Par Value	$ 750		750
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value	22		24
Total Borrowings at Carrying Value	$ 22		$ 24

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	9 Months Ended
	Sep. 29, 2018USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Maximum Borrowing Capacity	$ 2,500,000,000
Line of Credit Facility, Expiration Date	Jul. 1, 2021
Letters of Credit Outstanding, Amount	$ 83,000,000
Line of Credit Facility, Amount Outstanding	$ 0
Commercial Paper Programs [Member]
Short-term Financing [Line Items]
Short-term Debt, Period to Maturity	8 days
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days

Debt, Interest Rate Swap Arrang

Debt, Interest Rate Swap Arrangements (Details) - USD ($) $ in Millions		Sep. 29, 2018	Dec. 31, 2017
Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 3,100	$ 3,100
Interest Rate Swap, Pay Rate at Period End		4.73%
Cross Currency Interest Rate Contract [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,200
Interest Rate Swap, Pay Rate at Period End		1.97%
Senior Notes [Member] | 4.50% Senior Notes Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	[1]	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		3.442%
Interest Rate Swap, Pay Rate at Period End	[1]	5.5458%
Interest Rate Swap, Fixed Receive Rate		4.50%
Senior Notes [Member] | 3.60% Senior Notes Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives		$ 1,100
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		2.515%
Interest Rate Swap, Pay Rate at Period End		4.6734%
Interest Rate Swap, Fixed Receive Rate		3.60%
Senior Notes [Member] | 3.00% Senior Notes Due 2023 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	[1]	$ 1,000
Interest Rate Swap, Pay Rate Spread above One-month LIBOR		1.764%
Interest Rate Swap, Pay Rate at Period End	[1]	3.9224%
Interest Rate Swap, Fixed Receive Rate		3.00%
[1]	The payments on $1.2 billion notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of September 29, 2018 from a weighted average of 4.73% to a weighted average of 1.97%.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	Feb. 03, 2014	Sep. 29, 2018
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net		$ 50
Promega Corp and Max-Plank-Gesellschaft [Member] | Life Technologies Corporation [Member]
Loss Contingency [Abstract]
Damages Awarded	$ 52
Loss Contingency Accrued	$ 52

Comprehensive Income and Shar_3

Comprehensive Income and Shareholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 26,445	$ 22,391	$ 25,413	$ 21,540
Cumulative effect of accounting changes			30
Other comprehensive income (loss) before reclassifications			(444)
Amounts reclassified from accumulated other comprehensive items			16
Total other comprehensive items	(28)	73	(428)	453
Balance	26,890	24,702	26,890	24,702
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(1,755)
Cumulative effect of accounting changes			(54)
Other comprehensive income (loss) before reclassifications			(447)
Total other comprehensive items			(447)
Balance	(2,256)		(2,256)
Unrealized Gains on Available-for-Sale Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(1)
Cumulative effect of accounting changes			1
Total other comprehensive items			0
Balance	0		0
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(50)
Cumulative effect of accounting changes			(11)
Amounts reclassified from accumulated other comprehensive items			6
Total other comprehensive items			6
Balance	(55)		(55)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(197)
Cumulative effect of accounting changes			(24)
Other comprehensive income (loss) before reclassifications			3
Amounts reclassified from accumulated other comprehensive items			10
Total other comprehensive items			13
Balance	(208)		(208)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,491)	(2,256)	(2,003)	(2,636)
Cumulative effect of accounting changes			(88)
Total other comprehensive items	(28)	73	(428)	453
Balance	$ (2,519)	$ (2,183)	$ (2,519)	$ (2,183)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Assets [Abstract]
Cash equivalents	$ 49	$ 22
Bank time deposits	2	2
Investments in mutual funds and other similar instruments	12	13
Warrants	11	2
Insurance contracts	122	116
Derivative contracts	22	10
Total Assets	218	165
Liabilities [Abstract]
Derivative contracts	185	139
Contingent consideration	34	35
Total Liabilities	219	174
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	49	22
Bank time deposits	2	2
Investments in mutual funds and other similar instruments	12	13
Total Assets	63	37
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	11	2
Insurance contracts	122	116
Derivative contracts	22	10
Total Assets	155	128
Liabilities [Abstract]
Derivative contracts	185	139
Total Liabilities	185	139
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	34	35
Total Liabilities	$ 34	$ 35

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 35	$ 6
Acquisitions	11	12
Payments	(8)	(1)
Change in fair value included in earnings	(4)	26
Ending Balance	$ 34	$ 43

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	$ (143)	$ (70)
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge	3,240	3,309
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability	(143)	(70)
Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)	34	43
Interest Rate Swaps [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	3,100	3,100
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	180	124
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	1,200
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	8
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	2,991	2,921
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	14	10
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	5	15
Fair Value, Measurements, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	22	10
Derivative Liabilities	$ 185	$ 139

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017
Currency Exchange Contracts [Member] | Cost of Sales [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 1	$ 4	$ 1	$ 2
Currency Exchange Contracts [Member] | Other Expense [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	(2)	33	25	104
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Hedged Debt in Fair Value Hedge	(8)	2	(57)	12
Gain (Loss) on Derivative, Net	8	(4)	60	(9)
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(3)	(3)	(9)	(9)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	50	$ (216)	250	$ (545)
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	5		8
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Expense [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 9		$ 12

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Sep. 29, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes Receivable - Carrying Value	$ 92	$ 89
Notes Receivable - Fair Value	97	93
Debt Obligations - Carrying Value	18,774	21,008
Debt Instrument, Fair Value Disclosure	18,938	21,623
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	18,323	20,024
Debt Instrument, Fair Value Disclosure	18,487	20,639
Commercial Paper Programs [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	429	960
Debt Instrument, Fair Value Disclosure	429	960
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Obligations - Carrying Value	22	24
Debt Instrument, Fair Value Disclosure	$ 22	$ 24

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Non-cash Investing and Financing Activities [Abstract]
Declared but unpaid dividends	$ 69	$ 61
Issuance of stock upon vesting of restricted stock units	167	120
Cash and Cash Equivalents	1,098		$ 1,335
Restricted Cash Included in Other Current Assets	11		24
Restricted Cash Included in Other Assets	2		2
Cash, Cash Equivalents and Restricted Cash	$ 1,111	$ 758	$ 1,361	$ 811
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsCurrent
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent

Restructuring and Other Costs_3

Restructuring and Other Costs, Net (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2018	Sep. 30, 2017	Sep. 29, 2018	Sep. 30, 2017	Nov. 02, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated				1.00%
Cost of Revenues		$ (1)		$ 7
Selling, General and Administrative Expenses		(4)		7
Restructuring and other (income) costs, net		(27)	$ 49	35	$ 95
Total Restructuring and Other Costs (Income), Net		(32)		49
Restructuring and Related Costs, Cash Costs	[1]			89
Restructuring and Related Costs, Other Costs (Income), Net				(40)
Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				47
Abandonment of Excess Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs				29
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	[2]			13
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		(2)		(2)
Restructuring and other (income) costs, net		(47)		(24)
Total Restructuring and Other Costs (Income), Net		(49)		(26)
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				2
Selling, General and Administrative Expenses		4		3
Restructuring and other (income) costs, net		18		39
Total Restructuring and Other Costs (Income), Net		22		44
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other (income) costs, net		1		5
Total Restructuring and Other Costs (Income), Net		1		5
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues		(1)		5
Selling, General and Administrative Expenses		5		16
Restructuring and other (income) costs, net		1		14
Total Restructuring and Other Costs (Income), Net		5		35
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		(11)		(10)
Restructuring and other (income) costs, net				1
Total Restructuring and Other Costs (Income), Net		$ (11)		$ (9)
Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs						$ 95
[1]	Excludes $40 million of income, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.
[2]	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	9 Months Ended
	Sep. 29, 2018USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 76
Costs incurred	89	[1]
Reserves reversed	(14)	[2]
Payments	(62)
Currency translation	(1)
Ending balance	88
Restructuring and Related Costs, Other Costs (Income), Net	(40)
Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	30
Costs incurred	47
Reserves reversed	(7)	[2]
Payments	(29)
Currency translation	(1)
Ending balance	$ 40
Restructuring Reserve, Expected Final Year of Payments	2,019
Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 40
Costs incurred	29
Reserves reversed	(6)	[2]
Payments	(20)
Currency translation	0
Ending balance	$ 43
Restructuring Reserve, Expected Final Year of Payments	2,027
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	$ 6	[3]
Costs incurred	13	[3]
Reserves reversed	(1)	[2],[3]
Payments	(13)	[3]
Currency translation	0
Ending balance	$ 5	[3]
Restructuring Reserve, Expected Final Year of Payments	2,019
[1]	Excludes $40 million of income, net, primarily associated with litigation-related matters, hurricane response costs, and non-cash compensation due at an acquired business.
[2]	Represents reductions in cost of plans.
[3]	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.